Press and publications

AMW GmbH expands management team and appoints Dr. Konstantin Petropoulos as Chief Executive Officer

AMW GmbH announced today that Dr. Konstantin Petropoulos has been appointed Chief Executive Officer (CEO) effective March 15, 2021 This expands Dr. Friedrich Tegel and Philipp Karbach to the existing management team.

read more

EMPLOYEES OF AMW DONATE THE PROCEEDS OF THE TOMBOLA IN THE AMOUNT OF 500 EURO

Employees of AMW GmbH, a globally active pharmaceutical company based in Warngau, donate the proceeds from a tombola to Holzkirchen.

read more

A thank you for the employees and region

First no company outing, then no Christmas party. Corona has also ruined beautiful traditions at the pharmaceutical developer AMW from Warngau. However, the company has created a replacement. Monday before Christmas, some employees were amazed when two Santas were in front of the camera with a history book to tune in to a Christmas Day via video message.

read more

Expansion of the partnership between AMW and Zentiva for Western Europe

Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.

read more

Two new managing directors at AMW GmbH in Warngau

Wilfried Fischer, founding partner of AMW GmbH in Warngau, has resigned from the management, but remains associated with the company as an important shareholder. His responsibilities will be taken over by the previous co-managing directors Friedrich Tegel and Philipp Karbach.

read more

Brussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau

The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.

read more